This Blood Test Could Catch Lung Cancer's Return

This Blood Test Could Catch Lung Cancer's Return months before a scan would. Researchers at NYU Langone Health have shown that a simple blood draw can spot the faint genetic traces of lingering lung cancer after surgery, giving doctors a head start on the disease's comeback that imaging cannot match.

The technique is a form of liquid biopsy: it hunts for fragments of tumor DNA drifting in the bloodstream and reads their whole-genome mutational signatures, a molecular fingerprint unique to each patient's cancer. The study, published this week in The Journal of Molecular Diagnostics, followed lung cancer patients across treatment stages with repeated blood draws to see whether the test could predict relapse more reliably than standard imaging.

The answer was yes, and the margins matter. A positive result for tumor DNA served as a highly sensitive biomarker for what doctors call minimal residual disease, flagging microscopic recurrence well before tumors grew large enough to appear on a scan. A clear test, on the other hand, strongly correlated with sustained remission. That split is exactly why doctors believe this Blood Test Could Catch Lung Cancer's Return earlier than any scan, and it could change how doctors handle the anxious months after an operation, when patients currently wait for periodic scans to learn whether the cancer is really gone.

Why surgeons want this in the clinic

Lead investigator Matija Snuderl framed the work as part of a wider shift in cancer care. "As oncology shifts towards personalized risk-adapted care, liquid biopsies are emerging as a critical tool to bridge the gap between treatment completion and clinical recurrence," he said, according to an Elsevier press release about the study.

The clinical payoff is two-sided. Patients with detectable residual disease could be steered toward targeted post-operative treatment earlier, while those with clear results might be spared the burden of unnecessary extra therapy and its side effects. Co-lead surgeon Harvey Pass argued that this sensitivity matters most in the earliest stages of the disease, where even small tumors carry a real risk of coming back: between five and nineteen percent of stage-one patients see their cancer return, according to the study.

There is also a quieter benefit. Replacing some of the uncertainty between scans with concrete biological data could ease the dread that shadows every follow-up appointment. And catching relapse when the disease burden is extremely low gives restarted treatment its best possible shot, substantially improving long-term survival odds.

The commercial race is already here

The NYU findings landed the same week that the blood-test business moved on its own. On October 20, the diagnostics company Freenome disclosed in a securities filing that it has launched SimpleScreen Lung, a blood-based screening test for lung cancer, along with a first-of-its-kind single-draw offering that screens for both lung and colorectal cancer at once, Kalkine reported.

In an independent validation cohort, the lung test caught about four in five stage-one cancers and more than nine in ten late-stage cases, while nearly every negative result proved correct. The colorectal test, evaluated in a trial enrolling more than forty-eight thousand participants, showed similar strength. The intended population is adults between fifty and eighty with a heavy smoking history, matching current screening guidelines.

That timing matters because screening still misses most of the people who will develop the disease. Low-dose CT scans are offered mainly to older heavy smokers, and the NYU team's approach targets a different gap entirely: not who might get cancer, but whose cancer is quietly returning. It is a different question from the one asked by a September study from the University of Hawaiʻi, which used RNA markers to flag future risk years ahead, as covered in this earlier report on blood tests that flag lung cancer risk a decade early.

Plenty of hurdles remain before this Blood Test Could Catch Lung Cancer's Return in a typical clinic. Liquid biopsies are not yet a replacement for imaging, the tests will need validation in larger and more diverse populations, and access will hinge on insurance coverage and cost. But the direction is unmistakable: the blood draw is becoming a window into the cancer's status in real time, and for patients living scan to scan, that window cannot open soon enough.

Related coverage: gene therapy that gave blind patients their sight back and the weight-loss drug hitting new highs in women.